Several chemical methods for detecting and quantifying biomarkers are routinely utilized in both protein chemistry and clinical diagnostics, particularly in cancer diagnoses and the assessment of cardiovascular disease progression. Currently, methods such as high-performance liquid chromatography (HPLC), enzyme-linked immunosorbent assay (ELISA), and mass spectrometry rely on sample collection from the vascular compartment1,2,3 by bulk fluid draw or the interstitial compartment by microdialysis. Microdialysis employs a semipermeable membrane tube of known length that is placed in a region of interest. Collection fluid is perfused through the tube over several minutes4 to collect the sample for analysis5, thus limiting temporal resolution. In this manner, samples collected only provide an averaged value over time of the local microenvironment and are limited by the perfusion rate and collection of sufficient sample volume. Moreover, these methods require the pooling of experimental data and signal averaging; therefore, they may fail to account for variability between subjects. Importantly, the time between sample collection and subsequent offline analysis precludes immediate clinical intervention and therapeutics.
In the present protocol, the use of a capacitive immunoprobe biosensor (CI probe) for the time-resolved electrical detection of specific bioactive peptides is outlined. Neuropeptide Y (NPY), released from post-ganglionic sympathetic neurons that innervate the vasculature, endocardium, cardiomyocytes, and intracardiac ganglia, is a major neuromodulatory peptide transmitter in the cardiovascular system6,7,8,9. The method presented here is designed to measure NPY, and the experimental feasibility is demonstrated in a porcine heart model. However, this approach applies to any bioactive peptide for which a selective antibody is available10. This method relies on the capacitive junction between a platinum wire probe and the conductive fluid at the functionalized tip11,12. In this application, the interaction was mediated through an antibody against the target neuropeptide (NPY), which was bound to the electrode tip, interfacing the conductive fluid environment. This functionalization was achieved through electrodeposition of reactive polydopamine onto the tip of the platinum wire probe10,13.
When the antibody-functionalized probe is placed in a region of interest in vivo, evoked endogenous NPY release leads to binding to the trapping antibodies on the probe tip, and the conductive fluid at the electrode surface is displaced by the NPY protein. Local alteration in the electrical environment results in the displacement of high-mobility, high-dielectric fluid with an immobile, statically charged molecule. This alters the electrode-fluid interface and, thus, its capacitance, which is measured as a change in charge current in response to a step-function command potential. A negative "reset" potential is employed immediately following each individual measurement cycle to repel bound NPY from the antibody through electrostatic interaction, thus clearing the antibody binding sites for subsequent rounds of measurement10. This effectively allows for the measurement of NPY in a time-resolved manner. The unique CI technique overcomes the limitations of the microdialysis-based immunochemical methods outlined above to measure dynamic biomarker levels from a single experiment without data pooling or signal averaging over several experiments9, providing data in nearly real time. Moreover, the ability to adapt this method to any biomarker of interest for which there exists an appropriate antibody on a time-resolved and localized scale provides a major technical advance in immunochemical measurement for the evaluation of disease progression and the guidance of therapeutic interventions.
The software for data acquisition and analysis was custom-written in IGOR Pro (a fully interactive software environment). An analog to digital converter (A/D) system issued a command voltage under computer control and acquired data from a custom amplifier. The amplifier possessed certain unique features. These included a feedback resistor (switchable) for each of the four acquisition channels, allowing for choosing 1 MOhm or 10 MOhm feedback voltage clamp circuits to integrate the variability of the electrode. A stage unit with a single head and mutual ground/reference circuit for all the four acquisition channels was also built to place the device close by the chest in a single physical module. A 1 MOhm feedback resistor setting was used to collect all the reported data.
The filter and gain settings were telegraphed from the amplifier and recorded within the data file. Data were filtered at 1 kHz via a 2-pole analog Bessel filter digitized at 10 kHz. The difference in potential between the probe and surrounding conductive solution creates a Helmholtz capacitive layer at the probe tip. Ligand binding to the antibody at the probe tip results in an altered local charge and, thus, a change in the Helmholtz capacitance. This change in the capacitive component of the circuit results in a shift in the magnitude of injected charge required to bring the probe to the potential in the step-function voltage protocol. Thus, the binding of a specific ligand to the functionalized probe results in an alteration in the electrode capacitance measurement as a change in peak capacitive current.